SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Schober, J. M. Articles by Lam, S. C.-T. Search for Related Content PubMed PubMed Citation Articles by Schober, J. M. Articles by Lam, S. C.-T. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 June 2002, Vol. 99, No. 12, pp. 4457-4465 HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Identification of integrin M2 as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions Joseph M. Schober, Ningyu Chen, Tatiana M. Grzeszkiewicz, Igor Jovanovic, Eugene E. Emeson, Tatiana P. Ugarova, Richard D. Ye, Lester F. Lau, and Stephen C.-T. Lam From the Departments of Pharmacology, Molecular Genetics, and Pathology, University of Illinois at Chicago, College of Medicine, Chicago, IL and the Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Department of Molecular Cardiology, Cleveland Clinic Foundation, Cleveland, OH.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Cysteine-rich 61 (Cyr61, CCN1) and connective tissue growth factor (CTGF, CCN2) are growth factor-inducible immediate-early gene products found in blood vessel walls and healing cutaneous wounds. We previously reported that the adhesion of endothelial cells, platelets, and fibroblasts to these extracellular matrix-associated proteins is mediated through integrin receptors. In this study, we demonstrated that both Cyr61 and CTGF are expressed in advanced atherosclerotic lesions of apolipoprotein E-deficient mice. Because monocyte adhesion and transmigration are important for atherosclerosis, wound healing, and inflammation, we examined the interaction of THP-1 monocytic cells and isolated peripheral blood monocytes with Cyr61 and CTGF. THP-1 cells and monocytes adhered to Cyr61- or CTGF-coated wells in an activation-dependent manner and this process was mediated primarily through integrin M2. Additionally, expression of M2 on human embryonic kidney 293 cells resulted in enhanced cell adhesion to Cyr61. Consistent with these data, a GST-fusion protein containing the I domain of the integrin M subunit bound specifically to immobilized Cyr61 or CTGF. We have also investigated the requirement of cell surface heparan sulfate proteoglycans (HSPGs) as coreceptors for monocyte adhesion to Cyr61. Pretreatment of monocytes with heparin or heparinase I resulted in partial inhibition of cell adhesion to Cyr61. However, monocytes, but not fibroblasts, were capable of adhering to a Cyr61 mutant deficient in heparin binding activity. Collectively, these results show that activated monocytes adhere to Cyr61 and CTGF through integrin M2 and cell surface HSPGs. However, unlike fibroblast adhesion to Cyr61, cell surface HSPGs are not absolutely required for this adhesion process. (Blood. 2002;99:4457-4465) © 2002 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Cysteine-rich 61 (Cyr61) and connective tissue growth factor (CTGF) belong to the Cyr61/CTGF/nephroblastoma-overexpressed (CCN) family of matricellular signaling molecules capable of mediating diverse biologic functions.1,2 Other members in this protein family include Nov, WISP-1, WISP-2, and WISP-3. These proteins are characterized by the presence of an N-terminal secretory signal, followed by 4 conserved structural domains, which include: (1) an insulinlike growth factor-binding protein homology domain, (2) a von Willebrand factor type C domain, (3) a thrombospondin type 1 repeat homology domain, and (4) a C-terminal domain with sequence similarities to growth factor cysteine knots. It has been suggested that the C-terminal domain may mediate protein-protein interaction.3 Moreover, 2 putative heparin-binding motifs are present in the C-terminal domain of Cyr61 and mutations of the basic amino acid residues in these motifs abolish heparin-binding affinity of Cyr61.4 WISP-2 and its human homolog are unique in that they lack the C-terminal domain.5,6 Both Cyr61 and CTGF have been identified as products of immediate-early genes that are transcriptionally induced in fibroblasts in response to serum growth factors.7,8 On synthesis, they are secreted and become associated with the cell surface and the extracellular matrix,9,10 suggesting that these proteins may mediate cell-matrix interaction. In functional studies, both Cyr61 and CTGF have been shown to support cell adhesion, induce cell migration, and augment growth factor-induced cell proliferation in vitro4,10-16 and induce angiogenesis in vivo.13,14 Consistent with the adhesive properties of these proteins, 2 other family members, WISP-2 and Nov, have also been found to promote the adhesion of osteoblasts and vascular smooth muscle cells, respectively.6,17 Recently, we have identified several integrins, namely v3, v5, IIb3, and 61, as cellular receptors mediating interaction of different cell types with Cyr61 and CTGF.4,12,15,16 In addition, cell surface heparan sulfate proteoglycans (HSPGs) are also required for 61-mediated adhesion of human skin fibroblasts to Cyr61.4 Identification of integrins as signaling receptors for Cyr61 and CTGF accounts for most, if not all, of the cellular and biologic activities of these extracellular matrix-associated proteins. Immunohistochemical studies have localized both Cyr61 and CTGF in the cardiovascular system of developing mouse embryos and adult mice.10,18 Interestingly, CTGF has been shown to be overexpressed in human advanced atherosclerotic lesions as compared to normal blood vessels.19 High expression of CTGF has also been observed under diverse pathologic conditions, suggesting that it may play an important role in various diseases such as systemic scleroderma,20 renal fibrosis,21 and hepatic fibrosis in biliary atresia.22 During cutaneous wound healing, the expression of Cyr61 and CTGF is up-regulated, and therefore these proteins may function downstream of transforming growth factor- and fibroblast growth factor, strong inducers of Cyr61 and CTGF, in wound repair.18,23 Because monocyte adhesion and transendothelial migration play a central role in inflammation, atherosclerosis, and wound healing, we sought to examine the interaction of THP-1 cells and peripheral blood monocytes with Cyr61 and CTGF. In this study, we demonstrated that in addition to CTGF, Cyr61 is expressed in atherosclerotic lesions of apolipoprotein E-deficient (apoE/) mice. Moreover, monocytes adhere to both Cyr61 and CTGF, and this process is mediated through integrin M2 and cell surface HSPGs. Thus, these findings identified Cyr61 and CTGF as novel ligands for integrin M2, underscoring the importance of these proteins in the pathophysiologic function of monocytes.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Antibodies and peptides The anti-M monoclonal antibodies 2LPM19c and 44a were obtained from Dako (Carpinteria, CA) and Sigma (St. Louis, MO), respectively. The anti-v3 (LM609), anti-X (CBR-p150/4G1), anti-1(6S6) and anti-2 (YFC118.3) function-blocking monoclonal antibodies were purchased from Chemicon (Temecula, CA). An antiglutathione S-transferase (anti-GST) polyclonal antibody raised in goats was from Amersham Pharmacia Biotech (Piscataway, NJ) and a rabbit antigoat IgG conjugated to horseradish peroxidase (HRP) was from Sigma. Polyclonal anti-Cyr61 and anti-CTGF antibodies were raised in rabbits and affinity purified as described previously.10 An antipeptide antibody (anti-Cyr61367-381), raised in rabbits against a peptide sequence corresponding to the extreme C-terminus of Cyr61 (F367PFYRLFNDIHKFRD381; single-letter amino acid codes), was affinity purified against the peptide. Echistatin, an RGD-containing snake venom peptide,24 was obtained from Sigma. Vitronectin and fibronectin were purchased from Sigma and Gibco BRL (Grand Island, NY), respectively. Heparin (sodium salt; from porcine intestinal mucosa) and heparinase I (EC 4.2.2.7) were from Sigma. Protein purification Recombinant Cyr61 and CTGF, synthesized in a baculovirus expression system using Sf9 insect cells, were purified from serum-free conditioned media by chromatography on Sepharose S as previously described.10,11 A Cyr61 mutant (Cyr61-DM) with alanine substitutions of the basic amino acid residues within the 2 putative heparin-binding motifs at residues 280-290 and residues 306-312 was constructed by splice-overlap extension mutagenesis as previously described.4 Recombinant I domain of the integrin-M subunit was expressed as a fusion protein with GST (GST-MI) and purified as previously described.25 Briefly, the region coding for the human M I domain sequence D132-A318 was amplified and inserted in the expression vector pGEX-4T-1 (Amersham Pharmacia Biotech). To express GST-MI, BL-21 Escherichia coli cells were transformed with the above vector and protein expression was induced with 1 mM isopropyl--D-thiogalactopyranoside for 4 hours at 37°C. The GST-MI fusion protein was affinity purified from cell lysates using glutathione-agarose (Sigma). Isolation of peripheral blood monocytes Acid-citrate-dextrose anticoagulated human blood was collected from healthy donors and centrifuged at 200g for 20 minutes. After removal of the platelet-rich plasma, the buffy coat and packed red cells were diluted 2-fold with phosphate-buffered saline (PBS; 10 mM sodium phosphate, pH 7.35, 0.15 M NaCl) and 25 mL of the cell suspension was layered onto 20 ml Ficoll-Paque (Amersham Pharmacia Biotech). Mononuclear cells were isolated by centrifugation through Ficoll-Paque at 400g for 60 minutes at 4°C, diluted with an equal volume of PBS containing 2 mM EDTA, and sedimented at 400g for 10 minutes. To remove residual platelets, the mononuclear cells were washed twice with modified Tyrode buffer (10 mM Hepes, pH 7.35, 135 mM NaCl, 2.9 mM KCl, 12 mM NaHCO2, 1 mM MgCl2, 1 mM CaCl2, 0.1% dextrose and 0.2% bovine serum albumin [BSA]) by centrifugation at 130g for 10 minutes. To separate lymphocytes from monocytes, the mononuclear cells were resuspended in modified Tyrode buffer and subjected to discontinuous density gradient centrifugation on Percoll (Amersham Pharmacia Biotech). Peripheral blood monocytes were isolated between Percoll density of 1.047 and 1.050 g/mL, washed twice with modified Tyrode buffer, and resuspended to a final concentration of 2 to 3 × 106 cells/mL. The purity of the monocyte preparations was more than 80% as measured by anti-CD14 (Sigma) staining in flow cytometry, and cell viability was more than 98% as judged by trypan blue exclusion. Cell culture and cell adhesion assay The THP-1 cells (American Type Culture Collection, Rockville, MD) were maintained in RPMI 1640 media (Mediatech, Herndon, VA) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 1% nonessential amino acid solution, 100 µM -mercaptoethanol, 1.5 g/L NaHCO2, and antibiotics. Cells were grown to 1 × 106/mL and serum starved for 24 hours prior to cell adhesion experiments. Microtiter wells (Immulon 2 Removawell strips, Dynex Technologies, Chantilly, VA) were coated with 10 µg/mL Cyr61 or CTGF for 2 hours at 37°C and blocked with 1% BSA for 1 hour at 37°C. THP-1 cells, suspended in modified Tyrode buffer containing 0.1% BSA and 1 mM CaCl2, were added to the wells (100 µL/well) and incubated for 20 minutes at 37°C. Nonadherent cells were removed by washing and adherent cells were fixed and stained with 1% methylene blue. Cellular dye was extracted with acid-ethanol and cell adhesion was quantified by A650 as described.26 For the adhesion of peripheral blood monocytes, Cyr61-coated wells were blocked with 0.15% polyvinyl alcohol (PVA, Sigma) for 30 minutes at 37°C and cell adhesion proceeded as described above. Adherent cells were quantified using the acid phosphatase assay27 by incubation with the substrate solution (0.1 M sodium acetate, pH 5.5, 10 mM p-nitrophenyl phosphate, and 0.1% Triton X-100; 100 µL/well) for 2 hours at 37°C. The reaction was stopped by the addition of 15 µL 1 N NaOH and A450 was measured. In inhibition studies, monocytes were preincubated with antibodies, peptides, or EDTA for 30 minutes at 37°C prior to addition to microtiter wells. The M2-expressing human embryonic kidney 293 cells used in the adhesion assay have been previously described.28 In cell adhesion experiments, microtiter wells were coated with 1 µg/mL Cyr61 and blocked with 0.5% polyvinylpyrrolidone (Sigma). The cells were labeled with NaCrO4 (0.5 mCi/mL [18.5 MBq/mL]), and the adhesion of 51Cr-labeled cells to Cyr61-coated wells was performed as described.28 Binding assay of GST-MI fusion protein to immobilized Cyr61 and CTGF Microtiter wells were coated with Cyr61 or CTGF for 24 hours at 4°C and blocked with 0.15% PVA for 30 minutes at 37°C. GST-MI fusion protein (1 µM), preincubated with or without antibodies for 30 minutes at 37°C, was added to the wells and incubated for 2 hours at 22°C. Unbound GST-MI was removed by washing with 30 mM Tris-HCl, pH 7.3, 0.2 M NaCl, 1 mM MgCl2, and 0.01% PVA. Bound GST-MI was detected by an enzyme-linked immunosorbent assay (ELISA) using a polyclonal anti-GST antibody followed by an HRP-conjugated secondary antibody. Bound antibodies were detected using o-phenylenediamine dihydrochloride (Sigma) as the substrate. The reaction was stopped by the addition of 25 µL 6 N HCl and A490 was measured. Immunohistochemistry studies Retired breeders of apoE/ mice were obtained from Jackson Laboratory (Bar Harbor, ME) and killed by cervical dislocation under ether anesthesia. Their hearts with aortas were removed, fixed in 4% formaldehyde, frozen, and sectioned at a thickness of 10 µm on a cryostat. Sectioning began at the juncture of the aorta to the heart and continued toward the aortic arch covering a distance of 400 to 500 µm. The frozen sections were collected onto poly-L-lysine-coated coverslips and advanced atherosclerotic lesions were located by light microscopy. The sections were treated with 0.03% H2O2 to inactivate endogenous peroxidase, blocked with 3% normal goat serum, and incubated with anti-Cyr61 and anti-CTGF antibodies for 1 hour at 22°C. After washing, bound antibodies were detected with a biotinylated goat antirabbit antibody followed by the avidin-biotin-peroxidase labeling system using diaminobenzidine as the substrate (Vector Laboratories, Burlingame, CA). The sections were counterstained with hematoxylin and eosin.10     Results Top Abstract Introduction Materials and methods Results Discussion References Immunohistochemical localization of Cyr61 and CTGF in advanced atherosclerotic lesions in apoE/ mice It has been reported that CTGF is overexpressed in advanced atherosclerotic lesions in humans,19 which is likely due to growth factor stimulation of endothelial cells, aortic smooth muscle cells and fibroblasts at the lesion sites. Because Cyr61 is also transcriptionally induced in fibroblasts in response to serum growth factors,7 we examined whether the expression of Cyr61 is up-regulated in advanced atherosclerotic lesions. In these studies, we used the apoE/ mice, which have been shown to develop advanced atherosclerotic lesions similar to those found in humans.29-32 Frozen sections of the mouse atherosclerotic lesions were taken through the midpoint of the aortic valve with the lesion occupying approximately 95% of the circumference of the aortic wall. As shown in Figure 1, panels A through C, both the subendothelial intimal space and the media were markedly thickened exhibiting characteristics of human atherosclerotic lesions. To examine the expression of Cyr61 and CTGF in the mouse lesions, immunohistochemical staining was performed with anti-Cyr61 and anti-CTGF polyclonal antibodies. These antibodies were raised against recombinant protein fragments corresponding to the central variable regions of these proteins. On immunoblots, anti-Cyr61 and anti-CTGF reacted specifically with Cyr61 and CTGF, respectively, and no cross-reactivity was detected.10 Intense staining for Cyr61 was observed primarily in the subintimal regions of the lesion (Figure 1B, arrows). Similarly, CTGF was stained positively in the subintimal regions (Figure 1C, arrows) and also to a lesser degree just medial to the external elastic membrane (Figure 1C, arrowheads). The coronary artery also developed lesions with eccentric thickening of the intima and media, which were also stained positively with both antibodies (Figure 1E,F). By contrast, control sections incubated with normal rabbit IgG displayed minimal staining (Figure 1A,D). View larger version (96K): [in this window] [in a new window]   Figure 1. Immunohistochemical localization of Cyr61 and CTGF in advanced atherosclerotic lesions of ApoE/ mice. Frozen serial sections were taken from the heart at the aortic valve where prominent atherosclerotic lesions had formed. Sections were treated with H2O2, blocked with normal goat serum, and incubated with normal rabbit IgG (A,D), anti-Cyr61 (B,E), or anti-CTGF (C,F). Antibody localization was detected with a biotinylated secondary antibody, followed by the avidin-biotin-HRP labeling system using diaminobenzidine as the substrate. The sections were counterstained with hematoxylin and eosin. Lesions located at the aortic valve (A-C) and coronary artery (D-F) are shown. To demonstrate further the specificity of Cyr61 expression in atherosclerotic lesions, immunohistochemistry was performed with an antipeptide antibody (anti-Cyr61367-381) directed against the C-terminus of Cyr61, a region of unique sequence identity in Cyr61. On immunoblots, anti-Cyr61367-381 reacted with as little as 10 ng Cyr61 with no cross-reactivity with as much as 1 µg CTGF (data not shown). As expected, intense staining of the mouse lesions was observed with anti-Cyr61367-381 (Figure 2B), and pretreatment of the antipeptide antibody with Cyr61 protein completely abolished this staining (Figure 2C). Together, these results indicate that both Cyr61 and CTGF are expressed in atherosclerotic lesions of apoE/ mice. View larger version (80K): [in this window] [in a new window]   Figure 2. Specificity of immunohistochemical staining of Cyr61 in mouse atherosclerotic lesions. Frozen serial sections, taken from the hearts of ApoE/ mice, were incubated with rabbit IgG (A) or anti-Cyr61367-381 (B,C). To demonstrate staining specificity in panel C, anti-Cyr61367-381 was preabsorbed with 5 µg/mL recombinant Cyr61 for 16 hours at 4°C prior to its application to the sections. Immunohistochemical staining was performed as described in the legend of Figure 1. Activation-dependent adhesion of THP-1 cells and peripheral blood monocytes to Cyr61 and CTGF We previously reported that Cyr61 and CTGF induce cell adhesion and migration through interaction with integrin receptors.4,12-16 Because monocyte/macrophage-derived foam cells are present in subintimal regions of atherosclerotic lesions where the expression of Cyr61 and CTGF are prominent, we examined possible interaction of these mononuclear blood cells with Cyr61 and CTGF. In initial studies, cultured THP-1 monocytic cells were used to establish optimal conditions for cell adhesion to these proteins. In these experiments, THP-1 cells were activated with 20 µM adenosine diphosphate (ADP) or 20 nM phorbol myristate acetate (PMA) and allowed to adhere to microtiter wells coated with recombinant Cyr61 or CTGF. As controls, cell adhesion to BSA-coated wells was performed. The adherent cells were fixed, stained with methylene blue, and quantified by measuring A650 of the extracted dye. Figure 3A shows that THP-1 cells adhered to both Cyr61- and CTGF-coated wells, but not to control wells coated with BSA. Moreover, cellular activation with ADP resulted in an approximate 3-fold enhancement of cell adhesion to both proteins. An approximate 4-fold increase in cell adhesion was also observed with PMA stimulation. In 3 separate experiments, we consistently observed higher adhesion of THP-1 cells to Cyr61- than to CTGF-coated wells. Thus, in later experiments, we used Cyr61 as the prototype substrate to mediate cell adhesion. View larger version (16K): [in this window] [in a new window]   Figure 3. Adhesion of THP-1 cells to Cyr61 and CTGF. (A) Washed THP-1 cells were incubated with vehicle buffer (control), 20 µM ADP, or 20 nM PMA as indicated and added to microtiter wells (1 × 105 cells/well) coated with 10 µg/mL Cyr61, CTGF, or BSA. Cell adhesion proceeded for 20 minutes at 37°C. (B) THP-1 cells were stimulated with 20 µM ADP, added to wells coated with the indicated concentrations of Cyr61, and allowed to adhere for 20 minutes at 37°C. (C) ADP-stimulated THP-1 cells were added to wells coated with 15 µg/mL Cyr61 or BSA and incubated for the indicated times. Nonadherent cells were removed by washing. Adherent cells were fixed, stained with methylene blue, and A650 of the extracted dye was measured. Data presented are means of triplicate determinations and error bars represent SEs. Figures are representative of 3 experiments. To further characterize the adhesion of THP-1 cells to Cyr61, we examined dose and time dependency of this process. As shown in Figure 3B, the adhesion of ADP-stimulated THP-1 cells to Cyr61 was dose dependent with saturable adhesion occurring at a coating concentration of approximately 15 µg/mL. Time-course studies in Figure 3C show that the adhesion process was transient, peaking at 20 minutes and declining thereafter. These results suggest that the adherent cells became detached from immobilized Cyr61 in a time-dependent manner. This transient nature of leukocyte adhesion has also been observed for T-lymphoblastoid Jurkat cell adhesion to vascular cell adhesion molecule-1 and to the CS-1 peptide of fibronectin.33 Having established conditions for the adhesion assay, we proceeded to examine the adhesion of human peripheral blood monocytes to Cyr61. Unless otherwise indicated, isolated monocytes were added to microtiter wells coated with 10 µg/mL Cyr61 and adhesion proceeded for 20 minutes at 37°C. Because of the limited recovery of peripheral blood monocytes from the isolation procedure, cell adhesion was quantified using a more sensitive method by measuring the acid phosphatase activity of the adherent cells. Figure 4 shows that unactivated monocytes adhered poorly to Cyr61-coated wells. However, cellular activation with 20 µM ADP or 1 µM formyl-Met-Leu-Phe (fMLP)34 resulted in a dramatic increase in monocyte adhesion to Cyr61-coated wells. Quantitation of acid phosphatase activities of adherent versus added cells indicated that approximately 40% to 50% of input monocytes adhered to Cyr61, and this level of cell adhesion was comparable to those using vitronectin or fibrinogen as the adhesive substrates (Figure 5A,C). Preincubation of the cell suspension with 2 mM EDTA completely abolished the adhesion of unactivated and activated monocytes to Cyr61 (Figure 4). These results indicate that the adhesion process is activation and divalent cation dependent, consistent with the involvement of integrin receptors. View larger version (16K): [in this window] [in a new window]   Figure 4. Activation-dependent adhesion of peripheral blood monocytes to Cyr61. Isolated monocytes were preincubated with or without 2 mM EDTA for 30 minutes, and added to microtiter wells (2-3 × 105 cells/well) coated with 10 µg/mL Cyr61 in the presence of vehicle buffer (control), 20 µM ADP, or 1 µM fMLP. After incubation for 20 minutes at 37°C, nonadherent cells were washed and adherent cells were detected by the acid phosphatase assay. Data shown are means of triplicate determinations and error bars represent SEs. Figure is representative of 2 experiments. View larger version (20K): [in this window] [in a new window]   Figure 5. Inhibition of monocyte adhesion to Cyr61. Isolated monocytes were preincubated with inhibitors for 30 minutes at 37°C, then activated with 20 µM ADP, and allowed to adhere for 20 minutes at 37°C to microtiter wells coated with 10 µg/mL Cyr61, 10 µg/mL vitronectin, or 15 µg/mL fibrinogen as indicated. Cell adhesion was measured by the acid phosphatase assay. (A) Monocytes were pretreated with vehicle buffer (control), 200 nM mouse IgG (mIgG), 200 nM LM609 (anti-v3), or 1 µM echistatin. Cell adhesion to Cyr61 (open bars) or vitronectin (closed bars) was performed. (B) Monocytes were pretreated with vehicle buffer (control), 200 nM mouse IgG (mIgG), 6S6 (anti-1), YFC118.3 (anti-2), or 2LPM19c (anti-M) for 30 minutes at 37°C. Cell adhesion to Cyr61 was performed. (C) Monocytes, pretreated with vehicle buffer (control), 200 nM mouse IgG, 2LPM19c (anti-M), or CBR-p150/4G1 (anti-X) for 30 minutes at 37°C, were allowed to adhere to Cyr61 (open bars) or fibrinogen (closed bars). Data shown are means of triplicate determinations and error bars represent SEs. Identification of M2 as the major integrin mediating monocyte adhesion to Cyr61 In previous studies, we demonstrated that the adhesion of endothelial cells, platelets, and fibroblasts to Cyr61 and CTGF is mediated through interaction with integrins v3, IIb3, and 61, respectively.4,12,15 It has been reported that human monocytes express a small quantity of functional v3.35 By flow cytometry analyses, we also found that ADP-activated monocytes stained positively with 2 anti-v3 monoclonal antibodies, LM609 and anti-VnR1 (results not shown). Thus, we evaluated the role of this integrin in mediating monocyte adhesion to Cyr61. Figure 5A shows that LM609 (anti-v3) caused little inhibition of the adhesion of ADP-activated monocytes to Cyr61. Likewise, echistatin, a high-affinity RGD-containing snake venom peptide,24 blocked monocyte adhesion to Cyr61 by only 20%. However, in parallel samples, both compounds effectively inhibited monocyte adhesion to vitronectin by more than 85%. These results suggest that integrin v3 is not the major adhesion receptor on monocytes mediating interaction with Cyr61. To identify which integrin(s) on monocytes may be involved in this adhesion process, we examined the effect of monoclonal antibodies directed against different integrin subunits. As shown in Figure 5B, monocyte adhesion to Cyr61 was completely blocked by an anti-2 antibody (YFC118.3), but not by mouse IgG or an anti-1 antibody (6S6). The lack of effect of 6S6 was not due to the inaccessibility of the antibody to 1 integrins on monocytes because it inhibited monocyte adhesion to fibronectin by about 60% in control samples (results not shown). In addition to the anti-2 antibody, 2 monoclonal antibodies directed against the M subunit, 2LPM19c (Figure 5B) and 44a (results not shown), also caused complete inhibition of monocyte adhesion to Cyr61. These results suggest that integrin M2 serves as an adhesion receptor on monocytes for interaction with Cyr61. Because integrins M2 and X2 share some common ligand specificity,36 we examined possible interaction of Cyr61 with X2 on monocytes. As shown in Figure 5C, an anti-X antibody (CBR-p150/4G1) had no significant effect on monocyte adhesion to Cyr61, whereas an anti-M antibody (2LPM19c) completely blocked this process. In control samples, both anti-X and anti-M antibodies exerted partial inhibition on monocyte adhesion to fibrinogen as expected. Thus, these findings indicate that monocyte adhesion to Cyr61 is mediated specifically by integrin M2. To substantiate the ability of M2 to support cell adhesion, we used human embryonic kidney 293 cells genetically engineered to express the M2 integrin. Figure 6A shows that mock-transfected 293 cells adhered poorly to Cyr61; however, the expression of M2 on 293 cells caused an approximate 5-fold enhancement of cell adhesion to Cyr61. The specificity of M2-mediated cell adhesion was further demonstrated by the capacity of 2 anti-M antibodies, 2LPM19c and 44a, to inhibit the adhesion of M2-expressing 293 cells to Cyr61 (Figure 6B). View larger version (15K): [in this window] [in a new window]   Figure 6. Adhesion of M2-expressing 293 cells to Cyr61. (A) 51Cr-labeled M2-expressing or mock-transfected cells were added to microtiter wells coated with 1 µg/mL Cyr61. Cell adhesion proceeded for 30 minutes at 37°C, followed by 3 washes to remove nonadherent cells. The adherent cells were solubilized with 2% sodium dodecyl sulfate, and 51Cr radioactivity was quantified in a  counter. Data are expressed as a percentage of added cells. (B) 51Cr-labeled M2-expressing 293 cells were incubated with the indicated concentrations of anti-M monoclonal antibodies for 15 minutes at 22°C and allowed to adhere to wells coated with 1 µg/mL Cyr61. Data shown are percentages of maximal cell adhesion in a control sample without the antibodies. Role of cell surface HSPGs on monocyte adhesion to Cyr61 We previously showed that 61-mediated fibroblast adhesion to Cyr61 requires cell surface HSPGs to serve as coreceptors.4 In this regard, 2 putative heparin-binding motifs are present in the C-terminal domain of Cyr61 to mediate interaction with cell surface HSPGs. To investigate whether HSPGs on monocytes are also required for cell adhesion to Cyr61, we examined the effect of heparin, which binds Cyr61 with high affinity. As we previously reported,4 heparin dose dependently inhibited fibroblast adhesion to Cyr61 and complete inhibition was attained at concentrations of 1 µg/mL or higher (Figure 7A). In parallel samples, we found that heparin also inhibited monocyte adhesion to Cyr61. However, it was much less effective in blocking monocyte adhesion, and only partial inhibition was observed at a heparin concentration as high as 10 µg/mL. When cells were treated with heparinase to remove cell surface HSPGs prior to addition to Cyr61-coated wells, fibroblast adhesion was inhibited by about 75%, whereas monocyte adhesion was reduced by only about 45% (Figure 7B). To further investigate the role of cell surface HSPGs on monocyte adhesion to Cyr61, we examined the ability of monocytes to adhere to Cyr61-DM with alanine substitutions of the basic amino acid residues in both heparin binding motifs of Cyr61 (Figure 7C). Cyr61-DM is deficient in heparin binding and incapable of supporting fibroblast adhesion.4 Figure 7C shows that monocytes adhered to both wild-type Cyr61 and Cyr61-DM, but higher coating concentrations of Cyr61-DM were required for cell adhesion to occur. These results suggest that cell surface HSPGs are also involved in M2-mediated monocyte adhesion to Cyr61; however, the interaction of HSPGs on monocytes with Cyr61 is not absolutely required for this adhesion process. View larger version (24K): [in this window] [in a new window]   Figure 7. Role of cell surface HSPGs in monocyte adhesion to Cyr61. (A) Isolated monocytes (open bars) or 1064SK fibroblasts (closed bars) were preincubated with the indicated concentrations of heparin for 30 minutes at 37°C and added to wells coated with 10 µg/mL Cyr61. Cell adhesion proceeded for 20 minutes at 37°C. Adherent monocytes were quantified by measuring A450 in the acid phosphatase assay. Adherent fibroblasts were fixed, stained with 1% methylene blue, and the extracted dye was quantified by measuring A650. (B) Cells were pretreated with or without 2 U/mL heparinase I for 30 minutes at 37°C and allowed to adhere to Cyr61-coated wells for 20 minutes at 37°C. (C) Amino acid sequence of wild-type Cyr61 (Cyr61-WT) at residues 278-314 with the 2 heparin-binding motifs underlined. The Cyr61 mutant protein (Cyr61-DM) contains mutations in both motifs where basic residues were substituted with alanine as shown by the bold letters. ADP-activated monocytes were allowed to adhere to microtiter wells coated with the indicated concentrations of Cyr61-WT or Cyr61-DM. Data shown are means of triplicate determinations and error bars represent SEs. Figures are representative of 3 experiments. Binding of the I domain of M to immobilized Cyr61 and CTGF The cell adhesion data above identify Cyr61 and CTGF as novel adhesive ligands for M2 on monocytes. The integrin M subunit contains an inserted or I domain that is important for ligand interaction.37 Thus, we examined direct binding of a GST fusion protein containing the I domain of the M subunit (GST-MI) to Cyr61 and CTGF in a solid phase binding assay. In these experiments, microtiter wells were coated with Cyr61 or CTGF and the binding of GST-MI was detected with an anti-GST antibody in an ELISA system. As shown in Figure 8, panels A and B, GST-MI bound to wells coated with either protein in a dose-dependent and saturable manner. In control samples, GST itself did not bind to either Cyr61- or CTGF-coated wells. To further demonstrate binding specificity, we tested the inhibitory effect of 2LPM19c, a monoclonal antibody directed against the I domain of M.38 Consistent with the cell adhesion data, preincubation of GST-MI with 2LPM19c completely inhibited GST-MI binding to Cyr61- and CTGF-coated wells (Figure 8C). As expected, the anti-2 antibody (YFC118.3) had no effect on GST-MI binding even though it blocked monocyte adhesion to both proteins. View larger version (17K): [in this window] [in a new window]   Figure 8. Binding of the MI domain to Cyr61 and CTGF. Microtiter wells were coated with the indicated concentrations of Cyr61 (A) or CTGF (B), and blocked with 0.15% PVA. GST-MI fusion protein or GST (1 µM each) was added and allowed to bind for 2 hours at 22°C. After washing, bound GST-MI or GST was detected using a polyclonal anti-GST antibody followed by an HRP-conjugated secondary antibody. Bound antibodies were detected using o-phenylenediamine dihydrochloride as the substrate and A490 was measured. (C) GST-MI was preincubated with vehicle buffer (control), 500 nM YFC118.3 (anti-2), or 2LPM19c (anti-M) for 30 minutes at 37°C prior to addition to wells coated with 30 µg/mL Cyr61 (open bars) or CTGF (closed bars). Data shown are means of triplicate determinations and error bars represent SEs. Because heparin caused partial inhibition on monocyte adhesion to Cyr61 (Figure 7A), we examined its inhibitory effect on GST-MI binding to wild-type Cyr61 and to the heparin binding-deficient Cyr61-DM protein. Figure 9 shows that GST-MI bound equally well to both wild-type Cyr61 and Cyr61-DM, but not to BSA, indicating that the M2 binding site(s) in Cyr61 is not dependent on the 2 heparin-binding motifs in its C-terminal domain. In the presence of heparin, partial inhibition of GST-MI binding to wild-type Cyr61, but not to Cyr61-DM, was observed. Thus, heparin binding to wild-type Cyr61 may impose steric hindrance to the M2 binding site(s) in Cyr61. Furthermore, these results eliminate the possibility that heparin exerts its inhibitory effect by binding to the GST-MI fusion protein. View larger version (27K): [in this window] [in a new window]   Figure 9. Binding of GST-MI to wild-type Cyr61 and Cyr61-DM. Microtiter wells were coated with 30 µg/mL BSA, Cyr61-WT, or Cyr61-DM, and blocked with 0.15% PVA. GST-MI (1 µM), preincubated with the indicated concentrations of heparin, was added to the wells and allowed to bind for 2 hours at 22°C. Bound GST-MI was detected by an ELISA using an anti-GST polyclonal antibody as described in the legend of Figure 8. Data shown are means of triplicate determinations and error bars represent SEs. Figure is representative of 2 experiments.     Discussion Top Abstract Introduction Materials and methods Results Discussion References Cyr61 and CTGF are extracellular matrix-associated signaling molecules that support cell adhesion, promote cell migration, and augment growth factor-induced cell proliferation by interacting with specific integrins on different cell types. In this study, we demonstrated that both Cyr61 and CTGF are expressed in advanced atherosclerotic lesions of apoE/ mice. Furthermore, we found that THP-1 monocytic cells and peripheral blood monocytes adhere to these proteins in an activation-dependent manner, and identified integrin M2 as the major adhesion receptor mediating monocyte adhesion to Cyr61. In support of these findings, we showed that expression of M2 in human embryonic kidney 293 cells resulted in M2-mediated cell adhesion to Cyr61. Additionally, the I domain of M binds specifically to immobilized Cyr61 and CTGF in a solid phase binding assay. Finally, we found that cell surface HSPGs are also involved in, but not absolutely required for, monocyte adhesion to Cyr61. These observations establish Cyr61 and CTGF as novel adhesive ligands for integrin M2 on activated monocytes and suggest a role for these proteins in the pathophysiologic function of monocytes. Both Cyr61 and CTGF are expressed in the blood vessels of mice.10,18 Furthermore, in human advanced atherosclerotic lesions, CTGF has been shown to be highly expressed in vascular smooth muscle cells as well as in endothelial cells at the luminal sites of the vessels and in the vasa vasorum of the plaque lesions.19 Using the apoE/ mouse model, we extended these observations and showed that both Cyr61 and CTGF are highly expressed in mouse atherosclerotic lesions. It should be noted that both Cyr61 and CTGF are products of growth factor-inducible immediate-early genes that are rapidly activated on the transcriptional level.7,8 Also, it is well established that the levels of growth factors and cytokines such as platelet-derived growth factor, transforming growth factor-, basic fibroblast growth factor, and interleukin 1 are elevated in atherosclerotic lesions.39 Thus, interaction of these growth regulatory molecules with endothelial cells, smooth muscle cells, and fibroblasts at the lesion sites would undoubtedly result in the up-regulation of Cyr61 and CTGF expression. Although the functional significance of these proteins in atherosclerosis remains to be determined, their ability to interact with different cell types in the vasculature suggests that they may participate in lesion development as well as the consequences of plaque rupture. In this regard, both Cyr61 and CTGF are angiogenic factors,13,14 and thus they may induce neovascularization in the fibrous plaques. Moreover, we previously demonstrated that activated platelets adhere to Cyr61 and CTGF through integrin IIb3.15 On plaque rupture, the exposure of these proteins in the underlying subendothelial matrix would likely lead to platelet adhesion and the formation of occluding thrombi. Leukocyte adhesion and migration are essential for their recruitment to atherosclerotic lesions and to areas of extravascular inflammation. These adhesive interactions are mediated primarily by leukocyte-specific 2 integrins.37 Cyr61 and CTGF are expressed in advanced atherosclerotic lesions and in the granulation tissue of the healing cutaneous wounds18,23; therefore, we investigated the interaction of monocytes with these proteins. The results of our studies show that isolated peripheral blood monocytes adhere to Cyr61 following cellular activation with ADP or fMLP. The observation of activation-dependent adhesion, coupled with the divalent cation dependency of this process, suggests the involvement of integrin receptors. Indeed, monoclonal antibodies directed against the M or 2 subunit specifically blocked monocyte adhesion to Cyr61, indicating that M2 is the major integrin on activated monocytes mediating the adhesion event. Activation of monocytes with fMLP, ADP, and PMA causes a conformational change of M2 through inside-out signaling mechanisms.34,37,40 Our findings that ADP- and fMLP-activated monocytes adhere strongly to Cyr61 as opposed to resting monocytes suggest that activated M2 binds Cyr61 with a higher affinity as compared to the unactivated receptor. An alternative explanation is that activation of monocytes increases cell surface expression of M2, thereby facilitating monocyte adhesion to Cyr61. However, this possibility is unlikely because increased M2 expression is not sufficient to promote M2-dependent cell adhesion to other adhesive ligands such as fibrinogen and intercellular adhesion molecule-1 (ICAM-1).40 All of the  subunits complexed to 2 integrins contain an approximately 200-amino acid insert or I domain in their N-terminal regions.37 Isolated I domains of several  subunits are capable of binding ligands,25,28,41-44 and their atomic resolution structures reveal a unique divalent cation coordination sphere designated the "metal-ion dependent adhesion site."45 In a solid phase binding assay, we demonstrated that a soluble GST-MI fusion protein binds specifically to immobilized Cyr61 and CTGF, confirming that these proteins are direct ligands of M2. Unlike the other integrins (ie, v3, v5, IIb3, and 61) that have previously been reported to mediate cellular interaction with Cyr61 and CTGF,4,12,15,16 M2 is the first I domain-containing integrin that serves as an adhesion receptor for the CCN family of matrix-associated proteins. At present, the integrin binding site(s) on Cyr61 and CTGF are not known. However, analogous to the findings that IIb3 and M2 binding to different sites on fibrinogen,28,46,47 we speculate that the I domain-containing M2 may bind to a unique site on Cyr61 and CTGF than those recognized by other integrins without the I domain. Increasing evidence suggests that cell surface HSPGs such as syndecan-4 may act cooperatively with integrins to promote focal adhesion formation.48 Recently, we demonstrated that 61-mediated fibroblast adhesion to Cyr61 requires cell surface HSPGs to act as coreceptors for interaction with 2 heparin-binding motifs in the C-terminal domain of Cyr61.4 By contrast, adhesion of endothelial cells to Cyr61 through v3 is independent of the heparin binding activity of Cyr61.4 In the present study, we found that heparin partially blocked monocyte adhesion to Cyr61. Heparin may exert its inhibitory effect by binding to the heparin binding motifs in Cyr61 or by interacting with M2 on monocytes.49 The latter possibility has been excluded by the observation that heparin inhibited the binding of GST-IM to wild-type Cyr61 but not to the heparin binding-deficient Cyr61-DM protein. Moreover, treatments of monocytes with heparinase I to remove heparan sulfates from the cell surface resulted in partial inhibition of cell adhesion. Together, these findings indicate that HSPGs on monocytes also participate in optimal cell adhesion to Cyr61. Nevertheless, unlike fibroblast adhesion, monocytes are capable of adhering to Cyr61-DM that is deficient of heparin binding activity. Thus, while the binding of cell surface HSPGs to Cyr61 is involved in monocyte adhesion, such interaction is not necessary for this process. The relative affinities of different integrins with Cyr61 may account for the differential requirement of cell surface HSPGs for the adhesion of different cell types to Cyr61. Although the biologic significance of monocyte interaction with Cyr61 and CTGF remains to be established, the expression of these proteins in plaque lesions and healing wounds suggests that they may play an important role in atherosclerosis and inflammatory responses. In this regard, monocyte adhesion to activated endothelium and their emigration into the extravascular space are important for these processes. It has been reported that CTGF messenger RNA and protein are expressed in endothelial cells at the luminal site of atherosclerotic plaques,19 and therefore, it may act in concert with other adhesion molecules such as ICAM-1 to mediate monocyte adhesion through M2. Both Cyr61 and CTGF have been reported to stimulate cell migration through integrins,13,14,16 and it is likely that they would also induce transendothelial migration of monocytes. Once migrated, monocytes differentiate into macrophages; whether Cyr61 and CTGF play a regulatory role in this process is an intriguing possibility. Finally, these proteins are ligands of M2 on monocytes and would likely induce integrin-dependent outside-in signaling as has recently been shown in fibroblasts.50 In monocytes, integrin signaling leads to the expression of proinflammatory and proatherosclerotic substances such as interleukin 1.51 Based on these considerations, the potential role of CTGF and Cyr61, and perhaps other members of the CCN family, in the pathophysiologic function of monocytes merits further investigation.     Footnotes Submitted July 6, 2001; accepted February 4, 2002. Supported by grants HL-41793 (S.C.-T.L.), CA-46565 and CA-80080 (L.F.L.), and HL-63199 (T.P.U.) from the National Institutes of Health. J.M.S. has been supported by the National Institutes of Health HL-07829 training grant and by a predoctoral fellowship from the American Heart Association, Midwest Affiliate. Presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Stephen C.-T. Lam, Department of Pharmacology (M/C 868), University of Illinois at Chicago, 835 S Wolcott Ave, Chicago, IL 60612; e-mail: sclam{at}uic.edu.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Lau LF, Lam SC. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res. 1999;248:44-57[CrossRef][Medline] [Order article via Infotrieve]. 2. Brigstock DR. The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev. 1999;20:189-206[Abstract/Free Full Text]. 3. Perbal B, Martinerie C, Sainson R, Werner M, He B, Roizman B. The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: a clue for a role of NOVH in cell-adhesion signaling. Proc Natl Acad Sci U S A. 1999;96:869-874[Abstract/Free Full Text]. 4. Chen N, Chen CC, Lau LF. Adhesion of human skin fibroblasts to Cyr61 is mediated through integrin 61 and cell surface heparan sulfate proteoglycans. J Biol Chem. 2000;275:24953-24961[Abstract/Free Full Text]. 5. Zhang R, Averboukh L, Zhu W, et al. Identification of rCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation. Mol Cell Biol. 1998;18:6131-6141[Abstract/Free Full Text]. 6. Kumar S, Hand AT, Connor JR, et al. Identification and cloning of a connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functions. J Biol Chem. 1999;274:17123-17131[Abstract/Free Full Text]. 7. O'Brien TP, Yang GP, Sanders L, Lau LF. Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol. 1990;10:3569-3577[Abstract/Free Full Text]. 8. Ryseck RP, Macdonald-Bravo H, Mattei MG, Bravo R. Structure, mapping, and expression of fisp-12, a growth factor-inducible gene encoding a secreted cysteine-rich protein. Cell Growth Differ. 1991;2:225-233[Abstract]. 9. Yang GP, Lau LF. Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ. 1991;2:351-357[Abstract]. 10. Kireeva ML, Latinkic BV, Kolesnikova TV, et al. Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development. Exp Cell Res. 1997;233:63-77[CrossRef][Medline] [Order article via Infotrieve]. 11. Kireeva ML, MO FE, Yang GP, Lau LF. Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol. 1996;16:1326-1334[Abstract]. 12. Kireeva ML, Lam SC, Lau LF. Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin v3. J Biol Chem. 1998;273:3090-3096[Abstract/Free Full Text]. 13. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1998;95:6355-6360[Abstract/Free Full Text]. 14. Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin v3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol. 1999;19:2958-2966[Abstract/Free Full Text]. 15. Jedsadayanmata A, Chen CC, Kireeva ML, Lau LF, Lam SC. Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin IIb3. J Biol Chem. 1999;274:24321-24327[Abstract/Free Full Text]. 16. Grzeszkiewicz TM, Kirschling DJ, Chen N, Lau LF. CYR61 stimulates human skin fibroblast migration through integrin V5 and enhances mitogenesis through integrin V3, independent of its carboxy-terminal domain. J Biol Chem. 2001;276:21943-21950[Abstract/Free Full Text]. 17. Ellis PD, Chen Q, Barker PJ, Metcalfe JC, Kemp PR. Nov gene encodes adhesion factor for vascular smooth muscle cells and is dynamically regulated in response to vascular injury. Arterioscler Thromb Vasc Biol. 2000;20:1912-1919[Abstract/Free Full Text]. 18. Latinkic BV, Mo F-E, Greenspan JA, et al. Promoter function of the angiogenic inducer Cyr61 gene in transgenic mice: tissue specificity, inducibility during wound healing, and role of the serum response element. Endocrinology. 2001;142:2549-2557[Abstract/Free Full Text]. 19. Oemar BS, Werner A, Garnier JM, et al. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation. 1997;95:831-839[Abstract/Free Full Text]. 20. Igarashi A, Nashiro K, Kikuchi K, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol. 1995;105:280-284[CrossRef][Medline] [Order article via Infotrieve]. 21. Ito Y, Aten J, Bende RJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 1998;53:853-861[CrossRef][Medline] [Order article via Infotrieve]. 22. Tamatani T, Kobayashi H, Tezuka K, et al. Establishment of the enzyme-linked immunosorbent assay for connective tissue growth factor (CTGF) and its detection in the sera of biliary atresia. Biochem Biophys Res Commun. 1998;251:748-752[CrossRef][Medline] [Order article via Infotrieve]. 23. Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell. 1993;4:637-645[Abstract]. 24. Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem. 1988;263:19827-19832[Abstract/Free Full Text]. 25. Yakubenko VP, Solovjov DA, Zhang L, Yee VC, Plow EF, Ugarova TP. Identification of the binding site for fibrinogen recognition peptide 383-395 within the M I-domain of integrin M2. J Biol Chem. 2001;276:13995-14003[Abstract/Free Full Text]. 26. Oliver MH, Harrison NK, Bishop JE, Cole PJ, Laurent GJ. A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J Cell Sci. 1989;92:513-518[Abstract/Free Full Text]. 27. Connolly DT, Knight MB, Harakas NK, Wittwer AJ, Feder J. Determination of the number of endothelial cells in culture using an acid phosphatase assay. Anal Biochem. 1986;152:136-140[CrossRef][Medline] [Order article via Infotrieve]. 28. Ugarova TP, Solovjov DA, Zhang L, et al. Identification of a novel recognition sequence for integrin M2 within the -chain of fibrinogen. J Biol Chem. 1998;273:22519-22527[Abstract/Free Full Text]. 29. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471[Abstract/Free Full Text]. 30. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353[CrossRef][Medline] [Order article via Infotrieve]. 31. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140[Abstract/Free Full Text]. 32. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression [published erratum appears in Arterioscler Thromb 1994 May;14(5):839]. Arterioscler Thromb. 1994;14:141-147[Abstract/Free Full Text]. 33. Yakubenko VP, Lobb RR, Plow EF, Ugarova TP. Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon 41-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell Res. 2000;260:73-84[CrossRef][Medline] [Order article via Infotrieve]. 34. Altieri DC, Bader R, Mannucci PM, Edgington TS. Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol. 1988;107:1893-1900[Abstract/Free Full Text]. 35. Weerasinghe D, McHugh KP, Ross FP, Brown EJ, Gisler RH, Imhof BA. A role for the v3 integrin in the transmigration of monocytes. J Cell Biol. 1998;142:595-607[Abstract/Free Full Text]. 36. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem. 2000;275:21785-21788[Free Full Text]. 37. Harris ES, McIntyre TM, Prescott SM, Zimmerman GA. The leukocyte integrins. J Biol Chem. 2000;275:23409-23412[Free Full Text]. 38. Violette SM, Rusche JR, Purdy SR, Boyd JG, Cos J, Silver S. Differences in the binding of blocking anti-CD11b monoclonal antibodies to the A-domain of CD11b. J Immunol. 1995;155:3092-3101[Abstract]. 39. Raines EW, Ross R. Multiple growth factors are associated with lesions of atherosclerosis: specificity or redundancy? Bioessays. 1996;18:271-282[CrossRef][Medline] [Order article via Infotrieve]. 40. Diamond MS, Springer TA. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol. 1993;120:545-556[Abstract/Free Full Text]. 41. Zhou L, Lee DH, Plescia J, Lau CY, Altieri DC. Differential ligand binding specificities of recombinant CD11b/CD18 integrin I-domain. J Biol Chem. 1994;269:17075-17079[Abstract/Free Full Text]. 42. Kamata T, Liddington RC, Takada Y. Interaction between collagen and the 2 I-domain of integrin 21. Critical role of conserved residues in the metal ion-dependent adhesion site (MIDAS) region. J Biol Chem. 1999;274:32108-32111[Abstract/Free Full Text]. 43. Mesri M, Plescia J, Altieri DC. Dual regulation of ligand binding by CD11b I domain. Inhibition of intercellular adhesion and monocyte procoagulant activity by a factor X-derived peptide. J Biol Chem. 1998;273:744-748[Abstract/Free Full Text]. 44. Stanley P, Hogg N. The I domain of integrin LFA-1 interacts with ICAM-1 domain 1 at residue Glu-34 but not Gln-73. J Biol Chem. 1998;273:3358-3362[Abstract/Free Full Text]. 45. Lee JO, Rieu P, Arnaout MA, Liddington R. Crystal structure of the A domain from the  subunit of integrin CR3 (CD11b/CD18). Cell. 1995;80:631-638[CrossRef][Medline] [Order article via Infotrieve]. 46. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the  chain. Biochemistry. 1984;23:1767-1774[CrossRef][Medline] [Order article via Infotrieve]. 47. Altieri DC, Plescia J, Plow EF. The structural motif glycine190-valine202 of the fibrinogen  chain interacts with CD11b/CD18 integrin (M2, Mac-1) and promotes leukocyte adhesion. J Biol Chem. 1993;268:1847-1853[Abstract/Free Full Text]. 48. Woods A, Couchman JR. Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. Mol Biol Cell. 1994;5:183-192[Abstract]. 49. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol. 1995;130:1473-1482[Abstract/Free Full Text]. 50. Chen CC, Chen N, Lau LF. The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts. J Biol Chem. 2001;276:10443-10452[Abstract/Free Full Text]. 51. Lin TH, Rosales C, Mondal K, Bolen JB, Haskill S, Juliano RL. Integrin-mediated tyrosine phosphorylation and cytokine message induction in monocytic cells. A possible signaling role for the Syk tyrosine kinase. J Biol Chem. 1995;270:16189-16197[Abstract/Free Full Text]. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: V. Juric, C.-C. Chen, and L. F. Lau Fas-Mediated Apoptosis Is Regulated by the Extracellular Matrix Protein CCN1 (CYR61) In Vitro and In Vivo Mol. Cell. Biol., June 15, 2009; 29(12): 3266 - 3279. [Abstract] [Full Text] [PDF] C. A. Droppelmann, J. Gutierrez, C. Vial, and E. Brandan Matrix Metalloproteinase-2-deficient Fibroblasts Exhibit an Alteration in the Fibrotic Response to Connective Tissue Growth Factor/CCN2 because of an Increase in the Levels of Endogenous Fibronectin J. Biol. Chem., May 15, 2009; 284(20): 13551 - 13561. [Abstract] [Full Text] [PDF] M.-Y. Wang, P.-S. Chen, E. Prakash, H.-C. Hsu, H.-Y. Huang, M.-T. Lin, K.-J. Chang, and M.-L. Kuo Connective Tissue Growth Factor Confers Drug Resistance in Breast Cancer through Concomitant Up-regulation of Bcl-xL and cIAP1 Cancer Res., April 15, 2009; 69(8): 3482 - 3491. [Abstract] [Full Text] [PDF] K. Zen, D.-Q. Liu, L.-M. Li, C. X.-J. Chen, Y.-L. Guo, B. Ha, X. Chen, C.-Y. Zhang, and Y. Liu The Heparan Sulfate Proteoglycan Form of Epithelial CD44v3 Serves as a CD11b/CD18 Counter-receptor during Polymorphonuclear Leukocyte Transepithelial Migration J. Biol. Chem., February 6, 2009; 284(6): 3768 - 3776. [Abstract] [Full Text] [PDF] H. Matsumae, Y. Yoshida, K. Ono, K. Togi, K. Inoue, Y. Furukawa, Y. Nakashima, Y. Kojima, M. Nobuyoshi, T. Kita, et al. CCN1 Knockdown Suppresses Neointimal Hyperplasia in a Rat Artery Balloon Injury Model Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1077 - 1083. [Abstract] [Full Text] [PDF] S. A. Black Jr. and P. C. Trackman Transforming Growth Factor-{beta}1 (TGF{beta}1) Stimulates Connective Tissue Growth Factor (CCN2/CTGF) Expression in Human Gingival Fibroblasts through a RhoA-independent, Rac1/Cdc42-dependent Mechanism: STATINS WITH FORSKOLIN BLOCK TGF{beta}1-INDUCED CCN2/CTGF EXPRESSION J. Biol. Chem., April 18, 2008; 283(16): 10835 - 10847. [Abstract] [Full Text] [PDF] H. Liu, R. Yang, B. Tinner, A. Choudhry, N. Schutze, and B. Chaqour Cysteine-Rich Protein 61 and Connective Tissue Growth Factor Induce Deadhesion and Anoikis of Retinal Pericytes Endocrinology, April 1, 2008; 149(4): 1666 - 1677. [Abstract] [Full Text] [PDF] L. McCallum, S. Price, N. Planque, B. Perbal, A. Pierce, A. D. Whetton, and A. E. Irvine A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation Blood, September 1, 2006; 108(5): 1716 - 1723. [Abstract] [Full Text] [PDF] V. P. Yakubenko, S. P. Yadav, and T. P. Ugarova Integrin {alpha}Dbeta2, an adhesion receptor up-regulated on macrophage foam cells, exhibits multiligand-binding properties Blood, February 15, 2006; 107(4): 1643 - 1650. [Abstract] [Full Text] [PDF] U. R. Pendurthi, T. T. Tran, M. Post, and L. V. M. Rao Proteolysis of CCN1 by Plasmin: Functional Implications Cancer Res., November 1, 2005; 65(21): 9705 - 9711. [Abstract] [Full Text] [PDF] M.-T. Lin, C.-Y. Zuon, C.-C. Chang, S.-T. Chen, C.-P. Chen, B.-R. Lin, M.-Y. Wang, Y.-M. Jeng, K.-J. Chang, P.-H. Lee, et al. Cyr61 Induces Gastric Cancer Cell Motility/Invasion via Activation of the Integrin/Nuclear Factor-{kappa}B/Cyclooxygenase-2 Signaling Pathway Clin. Cancer Res., August 15, 2005; 11(16): 5809 - 5820. [Abstract] [Full Text] [PDF] I. Ben-Shlomo and A. J. W. Hsueh Three's Company: Two or More Unrelated Receptors Pair with the Same Ligand Mol. Endocrinol., May 1, 2005; 19(5): 1097 - 1109. [Abstract] [Full Text] [PDF] I. Cicha, A. Yilmaz, M. Klein, D. Raithel, D. R. Brigstock, W. G. Daniel, M. Goppelt-Struebe, and C. D. Garlichs Connective Tissue Growth Factor Is Overexpressed in Complicated Atherosclerotic Plaques and Induces Mononuclear Cell Chemotaxis In Vitro Arterioscler Thromb Vasc Biol, May 1, 2005; 25(5): 1008 - 1013. [Abstract] [Full Text] [PDF] N. A. Wahab, B. S. Weston, and R. M. Mason Connective Tissue Growth Factor CCN2 Interacts with and Activates the Tyrosine Kinase Receptor TrkA J. Am. Soc. Nephrol., February 1, 2005; 16(2): 340 - 351. [Abstract] [Full Text] [PDF] L. V. M. Rao and U. R. Pendurthi Tissue Factor-Factor VIIa Signaling Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 47 - 56. [Abstract] [Full Text] [PDF] Y. Chen, D. J. Abraham, X. Shi-wen, J. D. Pearson, C. M. Black, K. M. Lyons, and A. Leask CCN2 (Connective Tissue Growth Factor) Promotes Fibroblast Adhesion to Fibronectin Mol. Biol. Cell, December 1, 2004; 15(12): 5635 - 5646. [Abstract] [Full Text] [PDF] N. Chen, S.-J. Leu, V. Todorovic, S. C.-T. Lam, and L. F. Lau Identification of a Novel Integrin {alpha}v{beta}3 Binding Site in CCN1 (CYR61) Critical for Pro-angiogenic Activities in Vascular Endothelial Cells J. Biol. Chem., October 15, 2004; 279(42): 44166 - 44176. [Abstract] [Full Text] [PDF] S.-J. Leu, N. Chen, C.-C. Chen, V. Todorovic, T. Bai, V. Juric, Y. Liu, G. Yan, S. C.-T. Lam, and L. F. Lau Targeted Mutagenesis of the Angiogenic Protein CCN1 (CYR61): SELECTIVE INACTIVATION OF INTEGRIN {alpha}6{beta}1-HEPARAN SULFATE PROTEOGLYCAN CORECEPTOR-MEDIATED CELLULAR FUNCTIONS J. Biol. Chem., October 15, 2004; 279(42): 44177 - 44187. [Abstract] [Full Text] [PDF] G. Dai, M. R. Kaazempur-Mofrad, S. Natarajan, Y. Zhang, S. Vaughn, B. R. Blackman, R. D. Kamm, G. Garcia-Cardena, and M. A. Gimbrone Jr. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature PNAS, October 12, 2004; 101(41): 14871 - 14876. [Abstract] [Full Text] [PDF] N. Strunnikova, C. Zhang, D. Teichberg, S. W. Cousins, J. Baffi, K. G. Becker, and K. G. Csaky Survival of Retinal Pigment Epithelium after Exposure to Prolonged Oxidative Injury: A Detailed Gene Expression and Cellular Analysis Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3767 - 3777. [Abstract] [Full Text] [PDF] S. Kubota, K. Kawata, T. Yanagita, H. Doi, T. Kitoh, and M. Takigawa Abundant Retention and Release of Connective Tissue Growth Factor (CTGF/CCN2) by Platelets J. Biochem., September 1, 2004; 136(3): 279 - 282. [Abstract] [Full Text] [PDF] V. L. Tsikitis, N. A. Morin, E. O. Harrington, J. E. Albina, and J. S. Reichner The Lectin-Like Domain of Complement Receptor 3 Protects Endothelial Barrier Function from Activated Neutrophils J. Immunol., July 15, 2004; 173(2): 1284 - 1291. [Abstract] [Full Text] [PDF] S. Sakamoto, M. Yokoyama, X. Zhang, K. Prakash, K. Nagao, T. Hatanaka, R. H. Getzenberg, and Y. Kakehi Increased Expression of CYR61, an Extracellular Matrix Signaling Protein, in Human Benign Prostatic Hyperplasia and Its Regulation by Lysophosphatidic Acid Endocrinology, June 1, 2004; 145(6): 2929 - 2940. [Abstract] [Full Text] [PDF] D. Hilfiker-Kleiner, K. Kaminski, A. Kaminska, M. Fuchs, G. Klein, E. Podewski, K. Grote, I. Kiian, K. C. Wollert, A. Hilfiker, et al. Regulation of Proangiogenic Factor CCN1 in Cardiac Muscle: Impact of Ischemia, Pressure Overload, and Neurohumoral Activation Circulation, May 11, 2004; 109(18): 2227 - 2233. [Abstract] [Full Text] [PDF] S. Croci, L. Landuzzi, A. Astolfi, G. Nicoletti, A. Rosolen, F. Sartori, M. Y. Follo, N. Oliver, C. De Giovanni, P. Nanni, et al. Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells Cancer Res., March 1, 2004; 64(5): 1730 - 1736. [Abstract] [Full Text] [PDF] S. Sakamoto, M. Yokoyama, K. Prakash, J.-I. Tsuruha, S. Masamoto, R. H. Getzenberg, and Y. Kakehi Development of Quantitative Detection Assays for CYR61 as a New Marker for Benign Prostatic Hyperplasia J Biomol Screen, December 1, 2003; 8(6): 701 - 711. [Abstract] [PDF] S.-J. Leu, Y. Liu, N. Chen, C.-C. Chen, S. C.-T. Lam, and L. F. Lau Identification of a Novel Integrin {alpha}6{beta}1 Binding Site in the Angiogenic Inducer CCN1 (CYR61) J. Biol. Chem., September 5, 2003; 278(36): 33801 - 33808. [Abstract] [Full Text] [PDF] J. M. Schober, L. F. Lau, T. P. Ugarova, and S. C.-T. Lam Identification of a Novel Integrin {alpha}M{beta}2 Binding Site in CCN1 (CYR61), a Matricellular Protein Expressed in Healing Wounds and Atherosclerotic Lesions J. Biol. Chem., July 3, 2003; 278(28): 25808 - 25815. [Abstract] [Full Text] [PDF] P. Finckenberg, K. Inkinen, J. Ahonen, S. Merasto, M. Louhelainen, H. Vapaatalo, D. Muller, D. Ganten, F. Luft, and E. Mervaala Angiotensin II Induces Connective Tissue Growth Factor Gene Expression via Calcineurin-Dependent Pathways Am. J. Pathol., July 1, 2003; 163(1): 355 - 366. [Abstract] [Full Text] [PDF] C. G. Lin, S.-J. Leu, N. Chen, C. M. Tebeau, S.-X. Lin, C.-Y. Yeung, and L. F. Lau CCN3 (NOV) Is a Novel Angiogenic Regulator of the CCN Protein Family J. Biol. Chem., June 20, 2003; 278(26): 24200 - 24208. [Abstract] [Full Text] [PDF] F.-E Mo, A. G. Muntean, C.-C. Chen, D. B. Stolz, S. C. Watkins, and L. F. Lau CYR61 (CCN1) Is Essential for Placental Development and Vascular Integrity Mol. Cell. Biol., December 15, 2002; 22(24): 8709 - 8720. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Schober, J. M. Articles by Lam, S. C.-T. Search for Related Content PubMed PubMed Citation Articles by Schober, J. M. Articles by Lam, S. C.-T. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020